Multidisciplinary

Role of gliclazide MR today: Efficacy and safety you can trust

20170104013537
At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).

Related MIMS Drugs